A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, displays a dose of COVID-19 inactivated vaccine in Schering bottle package in Beijing, capital of China, Dec. 23, 2020. (Xinhua/Zhang Yuwei)
For infections requiring some medical intervention, it is about 84 percent and for moderate-to-severe COVID cases, it is 100 percent, an Australian expert said.
BEIJING, April 15 (Xinhua) -- China's Sinovac COVID-19 vaccine produced by Chinese company Sinovac Biotech works well with clinical coronavirus symptoms, especially in moderate-to-severe cases, Bloomberg News reported on Tuesday.
The efficacy data of about 50 percent of the vaccine is for very mild disease, requiring no treatment, Fiona Russell from the Murdoch Children's Research Institute in Melbourne was quoted as saying.
For infections requiring some medical intervention, it is about 84 percent and for moderate-to-severe COVID cases, it is 100 percent, Russell said.
Paul Griffin, a professor from the University of Queensland in Brisbane, told Bloomberg that "if the vaccine is approved by relevant regulators, then I think we need to have faith that it's safe and effective in that population." ■
